News

Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive AI-Driven Drug Discovery (AIDD) platform. During the event, Dr.
Enveric Biosciences ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, ...
The parenteral route of drug administration is considered ideal for biologics, as it enhances the bioavailability of therapeutic agents and maintains their stability. Additionally, a strong focus ...
I was scrolling through Instagram recently when I came across a video of a woman dramatically taking off her leggings and ...
Pharmacokinetic studies have shown that silymarin is absorbed by the oral route and that it distributes ... ethanol and psychotropic drugs. Numerous experimental studies suggest that it acts ...
Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...
Americans pay more for prescription drugs than people in Europe or in any other wealthy nation. Is that likely to change anytime soon? President Donald Trump took aim at that pricing disparity ...
Despite that, the first RNA-targeting therapeutic in the market was launched only five years ago, and the vast majority of ...
The president was flanked by Kennedy, Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz, Food and Drug Administration commissioner Dr. Marty Makary and National Institutes of ...
The Food and Drug Administration will also consider expanding drug importation from other countries besides Canada where drug prices are often cheaper, White House officials during a phone call to ...
The new executive order goes far beyond that measure since it is not limited to Medicare nor to a certain number of drugs. It’s also unclear what power the administration has to get involved in ...